Skip to main content
main-content

Oncology

Latest articles

16-08-2018 | Skin cancer | News | Article

Brief dermatologist-delivered intervention may improve sun protection behavior

The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.

Source:

JAMA Dermatol 2018; doi:10.1001/jamadermatol.2018.2331

16-08-2018 | Rheumatology | Highlight | Article

Editor's pick

TNF inhibitors unlikely to raise cancer recurrence risk in RA patients

Treatment with tumour necrosis factor inhibitors is not associated with a significantly increased risk of recurrent cancer among patients with rheumatoid arthritis, researchers report.

Source:

Ann Intern Med 2018; doi:10.7326/M17-2812

15-08-2018 | Oncology | News | Article

Apatinib–etoposide shows promise in platinum-resistant ovarian cancer

Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30349-8
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30444-3

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.2721
JAMA Surg 2018; doi:10.1001/jamasurg.2018.2728

13-08-2018 | Oncology | News | Article

Ibrutinib monotherapy promising for untreated Waldenström macroglobulinemia

Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6426
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3273

13-08-2018 | Oncology | News | Article

approvalsWatch

Mogamulizumab-kpkc approved for rare NHL subtypes

Read more on this US FDA decision here

image credits